<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">The pathogen reduction techniques being developed for labile components are likely effective against both viruses [
 <xref ref-type="bibr" rid="CR57">57</xref>]. Likewise, multiple steps in the manufacture of plasma derivatives should make their risk de minimis. These include wet heat, dry heat, lyophilization, solvent-detergent treatment, and nanofiltration. The purification steps used to manufacture plasma-derived medicinal products including cold ethanol or chemical precipitation and chromatographic steps should further mitigate risk.
</p>
